Home > Healthcare > Pharmaceuticals > Finished Drug Form > Anticoagulants Market

Anticoagulants Market Trends

Report ID: GMI4967
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Anticoagulants Market Trends

Recent breakthroughs in genetic testing and pharmacogenomics will positively impact the industry landscape through 2032. These advancements have paved the way for personalized medicine approaches in anticoagulation therapy. Genetic variations can influence an individual's response to anticoagulant medications, including the risk of bleeding or thrombotic events. Tailoring the choice and dosing of anticoagulants based on a patient's genetic profile can significantly improve treatment outcomes and reduce adverse events.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of anticoagulants was valued at around USD 39.2 billion In 2022 and will grow at over 9.5% CAGR from 2023 to 2032, attributed to the rising occurrence of chronic disorders globally.

Based on the drug category, industry size from the Factor Xa inhibitor segment will be worth about USD 58.4 billion by 2032, owing to its high availability.

North America market anticoagulants accounted for over 60.5% of the industry share in 2022, on account of rising healthcare spending in the region.

Major anticoagulants industry players include Johnson and Johnson, Boehringer Ingelheim, Daiichi Sankyo Company, Sanofi, Shenzhen Hepalink, Amphastar Pharmaceuticals, Inc., and Pfizer, among others.